Relationship between HbA1c and hypoglycaemia in patients with type 2 diabetes treated with different insulin regimens in combination with metformin

Diabetes/Metabolism Research and Reviews

Volumn 25, Issue 3, 2009, Pages 224-231

  Chan, John Y C ^a   Leyk, Malgorzata ^a,c   Frier, Brian M ^b   Tan, Meng H ^a,d  

^a ELI LILLY AND COMPANY   (United States)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Hypoglycaemia; Insulin glargine; Lispro insulin mixtures; Metformin; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; BEDTIME DOSAGE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; AGED; BLOOD; DIET RESTRICTION; METABOLISM; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED;

EID: 65649083773     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.929     Document Type: Article

References (22)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
2. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus - a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
3. Fritsche AM, Schweitzer MAM, Haring HUM, Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2003; 138: 952-959.
4. Riddle MCM, Rosenstock JM, Gerich JM, On Behalf of the Insulin Glargine Study Investigators. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
5. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 1716-1730.
6. Jacober SJ, Scism-Bacon JL, Zagar AJ. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naive patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes Obes Metab 2006; 8: 448-455.
7. Malone JK, Kerr LF, Campaigne BN, et al. Combined therapy with insulin lispro mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004; 26: 2034-2044.
8. Malone JK, Bai S, Campaigne BN, et al. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet Med 2005; 22: 374-381.
9. Raskin P, Hu P, Allen E, et al. Initiating insulin therapy in type 2 diabetes - A comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260-265.
10. Robbins D, Beisswenger P, Ceriello A, et al. Comparison of a mealtime basal + prandial insulin regimen (lispro mix 50/50) with a basal insulin regimen (glargine), both plus metformin, in type 2 diabetes patients: achieving HbA1c and pre- and postprandial blood glucose targets. Clin Ther 2007; 29: 2349-2364.
11. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007; 50: 1140-1147.
12. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes - pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005; 28: 2948-2961.
13. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
14. Lalli CM, Ciofetta MM, Del Sindaco PM, et al. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 1999; 22: 468-477.
15. Bennett PH. Classification and diagnosis of diabetes mellitus and impaired glucose tolerance. In Textbook of Diabetes, Pickup JC, Williams G (eds). Blackwell Scientific Publications: Oxford, UK, 1991; 37-44.
16. Miller CD, Phillips LS, Ziemer DC, et al. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001; 161: 1653-1659.
17. Henderson JN, Allen KV, Deary IJ, et al. Hypoglycaemia in insulin-treated type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med 2003; 20: 1016-1021.
18. Abraira CM, Colwell JAM, Nuttall FQM, et al. Veterans affairs cooperative study on glycemic control and complications in Type II diabetes (VA CSDM): results of the feasibility trial. Diabetes Care 1995; 18: 1113-1123.
19. Raskin PR, Hollander PA, Lewin A, et al. Basal insulin or premix analogue therapy in type 2 diabetes patients. Eur J Intern Med 2007; 18: 56-62.
20. Donnelly LA, Morris AD, Frier BM, et al. Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population-based study. Diabet Med 2005; 22: 749-755.
21. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in Type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
22. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with Type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.